Development of Invasomal Encapsulated Antimicrobial Peptide Delivery of Bacitracin for Topical Application in Wound Healing

References

[1] N. Dragicevic and H. Maibach, “Combined use of nanocarriers and physical methods for percutaneous penetration enhancement,” Advanced Drug Delivery Review, vol. 127, pp. 58–84, 2018. ScienceDirect

[2] P. Lakshmi, B. Kalpana, and D. Prasanthi, “Invasomes-novel vesicular carriers for enhanced skin permeation,” Systematic Reviews in Pharmacy, vol. 4, p. 26, 2013.

[3] A. S. Janoff, Liposomes: Rational Design. Marcel Dekker, New York, Chap. 1, 1998.

[4] G. L. Berestein and I. J. Fuller, Liposomes in the therapy of infectious diseases and cancer. New York Press, 1989.

[5] M. J. Ostro, Liposomes: From biophysics to therapeutics. Marcel Dekker, New York, 1987.

[6] C. Armann, J. Roding, M. Ghyczy, and H. G. Pratzel, “Liposomes from soya phospholipids as percutaneous drug carriers,” Arzneim-Forsch/ Drug Res, vol. 40, pp. 1365–1368, 1990.

[7] R. L. Hamilton and L. Guo, “Preparation, properties and potential,” in Liposome Technology, vol. 1, CRC Press, Fl, 1984.

[8] J. De Gier, J. G. Mandersloot, and L. L. M. Van Deenen, “Lipid composition and permeability of liposomes,” Biochim Biophys Acta, vol. 150, pp. 666–675, 1968.

[9] U. Afreen and A. Krishna Shailaja, “Overall Review on Invasomes,” Research Journal of Nanoscience and Engineering, vol. 3, no. 4, pp. 5–9, 2019.

[10] DrugBank, assessed on 14/12/2025.

[11] B. Samir, A. El-Kamel, N. Zahran, and L. Heikal, “Resveratrol-loaded invasome gel: A promising nanoformulation for treatment of skin cancer,” Drug Delivery and Translational Research, 2024. Springer

[12] O. S. Salih and E. J. Al-Akkam, “Preparation, In vitro, and Ex vivo Evaluation of Ondansetron Loaded Invasomes for Transdermal Delivery,” Iraqi Journal of Pharmaceutical Sciences, vol. 32, no. 3, 2023. Iraqi Journal of Pharmaceutical Sciences

[13] H. Verma, P. Pal, and D. Joshi, “Formulation, Development and Evaluation of Invasomes Loaded Gel for Fungal Treatment,” Sch Acad J Pharm, vol. 11, no. 7, pp. 105–108, Jul. 2022.

[14] S. Babaie, A. Taghvimi, M. Charkhpour, A. Zarebkohan, P. Keyhanvar, and H. Hamishehkar, “Optimization of Influential Variables in the Development of Buprenorphine and Bupivacaine Loaded Invasome for Dermal Delivery,” Advanced Pharmaceutical Bulletin, vol. 11, no. 3, pp. 522–529, 2021.

[15] M. A. Tawfik, M. I. Tadros, M. I. Mohamed, and S. N. El-Helaly, “Low-Frequency versus High-Frequency Ultrasound-Mediated Transdermal Delivery of Agomelatine-Loaded Invasomes: Development, Optimization and in-vivo Pharmacokinetic Assessment,” International Journal of Nanomedicine, vol. 15, pp. 8893–8910, 2020. PubMed

[16] S. Babaie, A. Z. Del Bakhshayesh, J. W. Ha, H. Hamishehkar, and K. H. Kim, “Invasome: A Novel Nanocarrier for Transdermal Drug Delivery,” Nanomaterials, vol. 10, p. 34, 2020.

[17] S. Jain, S. Tripathi, and P. K. Tripathi, “Invasomes: Potential vesicular systems for transdermal delivery of drug molecules,” Journal of Drug Delivery Science and Technology, 2020.

[18] H. O. Ammar, M. I. Tadros, N. M. Salama, and A. M. Ghoneim, “Ethosome-Derived Invasomes as a Potential Transdermal Delivery System for Vardenafil Hydrochloride: Development, Optimization and Application of Physiologically Based Pharmacokinetic Modeling in Adults and Geriatrics,” Int J Nanomed, vol. 15, pp. 5671–5685, 2020. PubMed

[19] S. Nangare and S. Dugam, “Smart invasome synthesis, characterizations, pharmaceutical applications, and pharmacokinetic perspective: a review,” Future J Pharm Sci, vol. 6, Art. no. 123, 2020. Springer

[20] M. Targhotra and M. Gupta, “Development and characterization of effective topical formulation for adapalene loaded invasomes for acne management,” Indian J Pham Sci Res, vol. 10, no. 1, pp. 1–8, 2020.

[21] K. Vidya and P. K. Lakshmi, “Cytotoxic effect of transdermal invasomal anastrozole gel on MCF-7 breast cancer cell line,” Journal of Applied Pharmaceutical Science, vol. 9, no. 3, pp. 50–58, 2019.

[22] T. Limsuwan, P. Boonme, and T. Amnuaikit, “Enhanced stability of phenylethyl resorcinol in elastic vesicular formulations,” Tropic RN,al Journal of Pharmaceutical Research, vol. 17, no. 10, pp. 1895–1902, 2018.

[23] M. A. El-Nabarawi, R. N. Shamma, F. Farouk, and S. M. Nasralla, “Dapsone-Loaded Invasomes as a Potential Treatment of Acne: Preparation, Characterization, and In Vivo Skin Deposition Assay,” AAPS PharmSciTech, 2018. Springer

[24] G. A. Qadri, A. Ahad, M. Aqil, S. S. Imam, and S. Ali, “Invasomes of isradipine for enhanced transdermal delivery against hypertension: formulation, characterization, and in vivo pharmacodynamic study,” Artificial cells, Nanomedicine, and Biotechnology, vol. 45, no. 1, pp. 139–145, 2017.

[25] M. Kamran, A. Ahad, M. Aquil, S. S. Imam, Y. Sultana, and A. Ali, “Design, formulation and optimization of novel soft nano-carriers for transdermal olmesartanmedoxomil delivery: In vitro characterization and in vivo pharmacokinetic assessment,” Int J Pharm, vol. 505, nos. 1–2, pp. 147–158, 2016.

[26] S. Duangjit, T. Nimcharoenwan, N. Chomya, N. Locharoenrat, and T. Ngawhirunpat, “Design and development of optimal invasomes for transdermal drug delivery using computer program,” Asian Journal of Pharmaceutical Sciences, vol. 11, pp. 52–53, 2016.

[27] P. K. Lakshmi, V. Mounica, M. Y. Kumar, and D. Prasanthi, “Preparation and evaluation of curcumin invasomes,” Int J Drug Del, vol. 6, no. 2, pp. 113–120, 2014.

[28] B. Kalpana and P. K. Lakshmi, “Transdermal permeation enhancement of Tolterodine Tartrate through invasomes and iontophoresis,” Der Pharmacia Lettre, vol. 5, no. 6, pp. 119–126, 2013.

[29] D. Prasanthi and P. K. Lakshmi, “Iontophoretic Transdermal Delivery of Finasteride in Vesicular Invasomal Carriers,” Pharmaceutical Nanotechnology, vol. 1, pp. 136–150, 2013. Bentham Science

[30] S. F. Haag, B. Taskoparan, R. Bittl, C. Teutloff, R. Wenzel, A. Fahr, M. Chen, J. Lademann, M. Schäfer-Korting, and M. C. Meinke, “Stabilization of Reactive Nitroxides Using Invasomes to Allow Prolonged Electron Paramagnetic Resonance Measurements,” Skin Pharmacology and Physiology, vol. 24, pp. 312–321, 2011. Karger

@article{1723461,
      author = {Mona Bhattacharya, Dr. Sandeep Jain, Dr. Bharat K. Tyagi, Dr. Pradeep Chauhan},
      title = {Development of Invasomal Encapsulated Antimicrobial Peptide Delivery of Bacitracin for Topical Application in Wound Healing},
      journal = {Iconic Research And Engineering Journals},
      year = {2026},
      volume = {10},
      number = {3},
      pages = {3149-3156},
      issn = {2456-8880},
      url = {https://www.irejournals.com/formatedpaper/1723461.pdf},
      abstract = {Wound infections are a major clinical concern that can delay the normal healing process and increase the risk of complications. Bacitracin is a peptide antibiotic widely used for topical management of superficial bacterial infections; however, its therapeutic effectiveness at the wound site may be limited by poor penetration into deeper skin layers, instability, and rapid removal from the application site. The present research was aimed at developing an invasomal delivery system for enhanced topical delivery of bacitracin for wound healing. Invasomes are flexible vesicular nanocarriers composed of phospholipids, ethanol, and selected penetration-enhancing terpenes, which provide improved deformability and facilitate penetration across the skin barrier. Bacitracin was encapsulated into invasomal vesicles using an appropriate vesicle preparation technique and the developed formulations were evaluated for vesicle characteristics, particle size, polydispersity index, zeta potential, entrapment efficiency, morphology, deformability, pH, drug content, and in vitro drug-release characteristics. The optimized invasomal formulation was further incorporated into a suitable topical gel base to improve skin residence time and ease of application. The formulation was evaluated for its physicochemical characteristics, drug release, skin permeation, antimicrobial activity, and wound-healing potential. The invasomal system is expected to enhance the deposition and penetration of bacitracin into the skin while providing controlled and prolonged drug release at the wound site. Thus, bacitrans-loaded invasomal gel may represent a promising topical delivery approach for improving the antimicrobial effectiveness of bacitracin and supporting efficient wound healing.},
      month = {September},
  }